Mitochondrial health is the latest frontier in performance and longevity. If you have been following the biohacking space, you have seen the names: NAD+, MOTS-C, and SS-31. They promise better energy, faster recovery, and slower aging — all by targeting the mitochondria, the power plants of your cells.
But what does the evidence actually say? And if you decide to use these compounds, what should you monitor? The honest answer is that the human evidence is earlier than the marketing implies, but each compound has a distinct profile that determines both its potential and its monitoring needs.
NAD+ Precursors: The Energy Substrate
NAD+ (Nicotinamide Adenine Dinucleotide) is a fundamental coenzyme in cellular energy metabolism. It is essential for mitochondrial function, DNA repair through sirtuin activation, and hundreds of enzymatic reactions. NAD+ levels decline naturally with age, and the theory is that restoring them could slow aspects of aging and improve cellular energy (PubMed: NAD+ supplementation).
The most studied precursors are Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN). Both are well-tolerated in human trials, with the main side effects being mild gastrointestinal discomfort at higher doses. Neither requires significant blood work monitoring for safety.
Blood work on NAD+ precursors: There are no direct blood markers for NAD+ status that a standard lab panel covers. The expected changes are indirect — improved metabolic markers (fasting glucose, insulin, lipids) over months of use. Some users report improved energy and recovery, but these are subjective. If you want to know whether a NAD+ precursor is working for you, the best approach is tracking training performance, recovery, and subjective energy levels rather than looking for blood work changes.
MOTS-C: The Metabolic Regulator
MOTS-C is a mitochondrial-derived peptide (MDP) — a short peptide encoded by mitochondrial DNA that regulates metabolic processes in the cell. Unlike NAD+ precursors, MOTS-C has a specific and measurable effect: it improves insulin sensitivity and glucose disposal (PubMed: MOTS-C metabolic effects).
Early human trials show promising effects on metabolic health, particularly in the context of age-related insulin resistance. For athletes, the theoretical application is improved glucose handling, which could translate to better carb utilization during training and more favorable body composition.
Blood work on MOTS-C: Unlike NAD+ precursors, MOTS-C has measurable metabolic effects. Fasting glucose, fasting insulin, HbA1c, and HOMA-IR are the relevant monitoring markers. A well-functioning MOTS-C protocol should show stable or improving glucose markers over 8-12 weeks. If glucose markers worsen, the compound is either not working or product quality is the issue.
SS-31 (Elamipretide): The Cardiac Candidate
SS-31, also known as Elamipretide, targets cardiolipin — a phospholipid in the inner mitochondrial membrane that is critical for energy production. By stabilizing cardiolipin, SS-31 improves the efficiency of the electron transport chain and reduces mitochondrial oxidative stress (PubMed: SS-31 elamipretide trials).
This is the compound with the strongest human evidence — but the evidence is for specific indications. SS-31 has been studied in phase 2 and 3 clinical trials for primary mitochondrial myopathy, Barth syndrome, and age-related heart failure with preserved ejection fraction (HFpEF). The results show real improvements in mitochondrial function and exercise capacity in these patient populations.
Blood work on SS-31: In a cardiac context, relevant markers include CK (creatine kinase) and NT-proBNP (a heart failure marker). For healthy athletes using SS-31 off-label for performance, there are no established blood work monitoring protocols. Standard baseline metabolic panel and CK are reasonable safety checks, but SS-31 has a good safety profile in clinical trials with no significant organ toxicity signals at therapeutic doses.
Mitochondrial Compound Comparison
NAD+ Precursors vs. MOTS-C
| Marker | NAD+ (NMN/NR) | MOTS-C |
|---|---|---|
| Mechanism | NAD+ substrate — energy metabolism, sirtuin activation | Mitochondrial peptide — insulin sensitivity, metabolism |
| Human Evidence | Moderate — well-studied in aging, metabolic health | Early — limited human trials, promising metabolic data |
| Blood Work Changes | Subtle, indirect (metabolic markers drift) | Measurable — glucose, insulin, HbA1c |
| Side Effect Profile | Mild GI discomfort at high doses | Limited data but appears well-tolerated |
MOTS-C vs. SS-31 (Elamipretide)
| Marker | MOTS-C | SS-31 (Elamipretide) |
|---|---|---|
| Primary Action | Metabolic regulation — glucose disposal | Mitochondrial membrane stabilization — energy efficiency |
| Human Trial Phase | Phase 1-2 (metabolic) | Phase 2-3 (mitochondrial disease, HFpEF) |
| Strength of Evidence | Promising but preliminary | Strongest human data of the three — but for specific conditions |
| Athletic Application | Improved carb handling, body composition | Recovery, cardiac efficiency, exercise capacity |
| Monitoring Needed | Glucose, insulin, HbA1c — the markers it actually affects | CK, NT-proBNP (cardiac context), standard metabolic panel |
The Human Evidence Reality Check
Monitoring Strategy
- Baseline: Comprehensive metabolic panel, fasting glucose, HbA1c, CK
- For MOTS-C specifically: Add fasting insulin and HOMA-IR at baseline and 8-12 weeks — these are the markers most likely to change
- For SS-31 at high doses: Consider CK and NT-proBNP as safety markers, though neither has shown significant shifts in clinical trials
- For NAD+ precursors: Standard metabolic panel is sufficient — changes are subtle and slow